Neurocrine Bioscienc (NBIX) 47.91 $NBIX
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 47.91 (-1.96)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 47.91 (-1.96), TRGT: 0.96 (-1.25), CBIO: 2.20 (+0.32), PTN: 0.49 (-0.01), IDXX: 89.09 (-1.16), BIOD: 0.35 (+0.01)
Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 47.91 (-1.96)
After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 47.91 (-1.96)
Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 47.91 (-1.96), DB: 15.84 (-0.87)
Shares of NBIX Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 22, 1:24PM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on March 31st, 2016 at $38.80. In approximately 3 weeks, Neurocrine Biosciences has returned 23.50% as of today's recent price of $47.91.
NBIX: 47.91 (-1.96)
Watch for Neurocrine Biosciences to Potentially Pullback After Gaining 5.66% Yesterday
Comtex SmarTrend(R) - Mon Apr 04, 4:03PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $42.00 to a high of $44.30. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $41.68 on volume of 756,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosciences After 7.00% Gain
Comtex SmarTrend(R) - Thu Mar 31, 2:48PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $37.50 to a high of $39.88. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $38.81 on volume of 491,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
21.1% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Mon Mar 28, 1:34PM CDT
SmarTrend identified a Downtrend for Neurocrine Biosciences (NASDAQ:NBIX) on January 28th, 2016 at $44.16. In approximately 2 months, Neurocrine Biosciences has returned 21.06% as of today's recent price of $34.86.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference
PR Newswire - Wed Mar 09, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare Conference in Miami Beach.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference
PR Newswire - Wed Mar 02, 5:30PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Cowen and Company 36th Annual Health Care Conference in Boston.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 47.91 (-1.96)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 47.91 (-1.96), TRGT: 0.96 (-1.25), CBIO: 2.20 (+0.32), PTN: 0.49 (-0.01), IDXX: 89.09 (-1.16), BIOD: 0.35 (+0.01)
Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 47.91 (-1.96)
After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 47.91 (-1.96)
Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 47.91 (-1.96), DB: 15.84 (-0.87)
Shares of NBIX Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 22, 1:24PM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on March 31st, 2016 at $38.80. In approximately 3 weeks, Neurocrine Biosciences has returned 23.50% as of today's recent price of $47.91.
NBIX: 47.91 (-1.96)
Watch for Neurocrine Biosciences to Potentially Pullback After Gaining 5.66% Yesterday
Comtex SmarTrend(R) - Mon Apr 04, 4:03PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $42.00 to a high of $44.30. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $41.68 on volume of 756,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosciences After 7.00% Gain
Comtex SmarTrend(R) - Thu Mar 31, 2:48PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $37.50 to a high of $39.88. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $38.81 on volume of 491,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 47.91 (-1.96)
21.1% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Mon Mar 28, 1:34PM CDT
SmarTrend identified a Downtrend for Neurocrine Biosciences (NASDAQ:NBIX) on January 28th, 2016 at $44.16. In approximately 2 months, Neurocrine Biosciences has returned 21.06% as of today's recent price of $34.86.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference
PR Newswire - Wed Mar 09, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare Conference in Miami Beach.
NBIX: 47.91 (-1.96)
Neurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference
PR Newswire - Wed Mar 02, 5:30PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Cowen and Company 36th Annual Health Care Conference in Boston.
NBIX: 47.91 (-1.96)
